Mechanisms of development of side effects and drug resistance to asparaginase and ways to overcome them

   
Alexandrova S.S.1, Gladilina Y.A.1, Pokrovskaya M.V.1, Sokolov N.N.1, Zhdanov D.D.1

1. Institute of Biomedical Chemistry, Moscow, Russia
Section: Review
DOI: 10.18097/PBMC20226802104      PubMed Id: 35485484
Year: 2022  Volume: 68  Issue: 2  Pages: 104-116
Asparaginase is one of the most important chemotherapeutic agents against acute lymphoblastic leukemia, the most common form of blood cancer. To date, both asparaginases from E. coli and Dickeya dadantii (formerly known as Erwinia chrysanthemi), used in hematology, induce chemoresistance in cancer cells and side effects in the form of hypersensitivity of immune reactions. Leukemic cells may be resistant to asparaginase due to the increased activity of asparagine synthetase and other mechanisms associated with resistance to asparaginase. Therefore, the search for new sources of L-asparaginases with improved pharmacological properties remains a promising and prospective study. This article discusses the mechanisms of development of resistance and drug resistance to L-asparaginase, as well as possible ways to overcome them.
Download PDF:
Keywords: antitumor enzymes, L-asparaginase, drug resistance, immunogenicity
Citation:

Alexandrova, S. S., Gladilina, Y. A., Pokrovskaya, M. V., Sokolov, N. N., Zhdanov, D. D. (2022). Mechanisms of development of side effects and drug resistance to asparaginase and ways to overcome them. Biomeditsinskaya khimiya, 68(2), 104-116.
References  
 2022 (vol 68)
 2021 (vol 67)
 2020 (vol 66)
 2019 (vol 65)
 2018 (vol 64)
 2017 (vol 63)
 2016 (vol 62)
 2015 (vol 61)
 2014 (vol 60)
 2013 (vol 59)
 2012 (vol 58)
 2011 (vol 57)
 2010 (vol 56)
 2009 (vol 55)
 2008 (vol 54)
 2007 (vol 53)
 2006 (vol 52)
 2005 (vol 51)
 2004 (vol 50)
 2003 (vol 49)